Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.
Craig H. Reynolds
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - Lilly
Jyoti D. Patel
No relevant relationships to disclose
Edward B. Garon
Research Funding - Lilly
Mark R. Olsen
No relevant relationships to disclose
Philip D. Bonomi
Consultant or Advisory Role - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly
Ramaswamy Govindan
Consultant or Advisory Role - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Honoraria - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Coleman K. Obasaju
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Eduardo J. Pennella
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Susan C. Guba
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
David R. Spigel
Consultant or Advisory Role - Lilly
Robert C. Hermann
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Lilly; Roche/Genentech
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly